13.30 | 10.30 – Longitudinal Monitoring of Melanoma Patients Receiving Checkpoint Inhibitor Immunotherapies Using Cell Free MiRNA

Time: 1:30 pm
day: Day Two


  • Profiling of cf miRNA by NGS to identify signatures in metastatic melanoma patients of stage 3 and 4
  • Identification of cf miRNA signatures that correlate to checkpoint inhibitor immunotherapy responses
  • Early detection of progression disease failure during immunotherapy failure